How China's Hepatitis burden is a lesson for India's public health system

For New Delhi, Beijing's challenge reinforces that economic progress alone cannot guarantee better health outcomesAs Asia continues to shape the global economic landscape, public health remains one of the defining indicators of long-term national resilience. A recent forecast by healthcare analytics firm GlobalData has brought renewed attention to China’s Hepatitis C burden.The projection is that by 2035, the country could account for more than half of all diagnosed chronic Hepatitis C cases across eight major global pharmaceutical markets—over 3.9 million diagnosed patients. The findings highlight a significant healthcare challenge that extends beyond China’s borders and offers critical lessons for neighbouring countries, including India.Despite remarkable progress in infrastructure, manufacturing and technological innovation, China continues to grapple with the long-term consequences of historical public health shortcomings. Many health experts trace a significant share of Hepatitis C infections to unsafe blood collection practices and inadequate infection control during the 1980s and 1990s, when commercial plasma donation expanded rapidly in several provinces. Although China has since introduced stronger blood safety regulations and expanded access to treatment, the legacy of those infections continues to shape today’s disease burden.Incidentally, China’s economic growth slowed down sharply in the second quarter of 2026 (April-June) as weak domestic demand and the Iran war’s impact on oil prices overshadowed the country’s strong exports. Official gross domestic product (GDP) figures showed the world’s second largest economy grew in this period by 4.3 per cent, below Beijing’s annual target and as against a 5 per cent rise in the first quarter. Hepatitis C is often described as a ‘silent disease’ because many infected individuals experience no symptoms for years. Left untreated, the virus can gradually damage the liver, leading to cirrhosis, liver failure or liver cancer. Modern direct-acting antiviral medicines can cure more than 95 per cent of infections when diagnosed early, making timely screening and treatment critical to reducing long-term health complications.The GlobalData forecast underscores that diagnosis remains one of the greatest challenges. Millions of individuals may remain unaware of their infection until severe liver disease develops. Reaching vulnerable populations across vast rural regions continues to require sustained investment in healthcare infrastructure, trained personnel and community-based screening programmes.For India, China’s experience carries particular significance. India is also home to a large and geographically diverse population, with considerable disparities in healthcare access between metropolitan centres and rural districts. Although India’s estimated Hepatitis C prevalence remains substantially lower than China’s projected diagnosed burden, experts have repeatedly emphasised that delayed diagnosis and unequal healthcare access can allow preventable diseases to persist unnoticed.Over the past decade, India has taken notable steps to strengthen its response. The National Viral Hepatitis Control Programme (NVHCP), launched in 2018, aims to provide free screening, diagnosis and treatment for viral Hepatitis through public health facilities. The availability of affordable generic direct-acting antiviral drugs has also made treatment considerably more accessible than in many parts of the world.Public health specialists argue that India’s emphasis on affordable medicines and expanding primary healthcare networks offers valuable opportunities to reduce Hepatitis C-related mortality. However, they caution that sustained success depends on continuous surveillance, public awareness campaigns, safe blood transfusion practices and infection control measures across both public and private healthcare systems.China’s projected disease burden also raises broader questions about the relationship between economic development and healthcare preparedness. Rapid industrialisation and urban growth have transformed living standards for hundreds of millions of Chinese citizens, yet healthcare systems often face the difficult task of addressing historical disease burdens while simultaneously meeting the demands of an ageing population.Rural healthcare remains a common challenge across many large developing economies. Delivering specialised diagnostics and long-term treatment to remote communities requires substantial financial resources, trained healthcare workers and efficient referral systems. Experts note that strengthening these foundational elements is essential for tackling chronic diseases that may remain undetected for years.The issue extends beyond national boundaries. The World Health Organization (WHO) has set ambitious targets to eliminate viral Hepatitis as a public health threat by 2030. Achieving that objective depends not only on the availability of effective medicines but also on widespread screening, reliable surveillance systems and equitable access to healthcare services. Large countries with significant disease burdens will play a decisive role in determining whether these global targets can be achieved.For India, the Chinese experience reinforces an important public health lesson: economic progress alone cannot guarantee better health outcomes. Sustainable development requires continuous investment in preventive healthcare, disease surveillance and early diagnosis. The Covid-19 pandemic demonstrated how quickly health emergencies can place enormous pressure on even well-resourced systems, underscoring the importance of preparedness and transparency.Health policy experts believe India has an opportunity to strengthen its position by expanding Hepatitis screening among high-risk groups, improving awareness in rural communities and integrating viral Hepatitis services into broader primary healthcare initiatives. Continued investment in digital health records, laboratory capacity and frontline healthcare workers could further improve early detection and treatment outcomes.Experts pointed out that as Asia’s two largest economies continue their respective development journeys, their approaches to public health will increasingly influence regional health security and economic productivity. While China’s projected Hepatitis C burden reflects the enduring consequences of historical healthcare challenges, it also serves as a reminder that long-term investment in preventive medicine remains essential for every nation.Ultimately, the measure of a country’s strength lies not only in economic indicators or technological achievements but also in its ability to protect the health of its citizens. For India, the evolving Hepatitis C landscape across Asia landscape provides both a cautionary example and an opportunity to reinforce its own public health systems before preventable diseases impose a greater social and economic burden in the years ahead.Subscribe to India Today Magazine- EndsPublished By: Yashwardhan SinghPublished On: Jul 19, 2026 00:14 IST